Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 21, 2006

View Archived Issues

Preclinical melanoma, phase I NHL studies of PPI-2458 presented

Gene therapy approach successful for hip prosthesis loosening

BioMarin makes strides in third quarter

Kinases in rheumatology

Combined ramipril and candesartan better than monotherapy in hypertension

Rimonabant reduces liver enzymes in overweight, dyslipidemic patients

Aliskiren reduces renin activity in mono- and combination therapy

Mitsubishi's novel NF-kB inhibitor shows potent antiangiogenic and antitumor activity in vivo

Salvat's SVT-004703 shows antitumor activity by inhibiting tubulin polymerization

MethylGene and EnVivo collaborate with CHDI on Huntington's program

Roxro's intranasal ketorolac provides effective postsurgery pain relief

New therapeutic agents for thrombotic disorders disclosed in recent patent literature

Enrollment suspended in becatecarin phase III program in biliary tract tumors

Novel agents for obesity, lipoprotein disorders, etc. claimed

Novel monoclonal antibodies for renal diseases emerge from Lilly R&D

Clinical advisory meeting for Resverlogix's ApoA-I enhancing technologies

Emerging companies showcased at BIO-Europe 2006: Ablynx

Enrollment opens in pivotal MEND-CABG II study of MC-1

SGN-35 begins phase I study for CD30-positive hematologic malignancies

EVT-201 begins second phase II trial for insomnia

Bavituximab studied with chemotherapy in phase Ib cancer study

Novartis selects preclinical development candidate in Vernalis Hsp90 collaboration

Actelion to acquire CoTherix

Gilead Sciences completes Myogen acquisition

Ferumoxytol meets phase III endpoints in non dialysis-dependent CKD patients

First DC vaccine with clinical activity and therapeutic/chemopreventive potential

NeoRecormon recommended for once weekly use in solid tumor patients in E.U.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Hits’ Hyperlab launches as ‘virtual AI lab’ for new drug discovery
BioWorld Science
Things once done in laboratories can now be done with computers and AI, said Kim Woo-youn, CEO and cofounder of Hits Inc. “We live in the age of ‘digital...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...